Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Return on Sales (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Return on Sales data on record, last reported at 19.88% in Q4 2025.

  • For Q4 2025, Return on Sales rose 26641.0% year-over-year to 19.88%; the TTM value through Dec 2025 reached 60.4%, up 22589.0%, while the annual FY2025 figure was 60.46%, 22629.0% up from the prior year.
  • Return on Sales reached 19.88% in Q4 2025 per CRNX's latest filing, up from 909.73% in the prior quarter.
  • Across five years, Return on Sales topped out at 10.74% in Q1 2022 and bottomed at 909.73% in Q3 2025.
  • Average Return on Sales over 5 years is 160.17%, with a median of 96.41% recorded in 2022.
  • Peak YoY movement for Return on Sales: soared 101314bps in 2021, then plummeted -64696bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 28.58% in 2021, then tumbled by -125bps to 64.39% in 2022, then rose by 19bps to 52.12% in 2023, then crashed by -449bps to 286.29% in 2024, then soared by 93bps to 19.88% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 19.88% in Q4 2025, 909.73% in Q3 2025, and 112.18% in Q2 2025.